The new drug registration of step pharmaceutical subsidiary was terminated, and 7.6 million R & D expenses have been invested

Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis

‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’

HastenPharma Secures USD 315 Mn in Financing to Focus on M&A Business and R&D

Anhui-based biopharmaceutical company HastenPharma(海森生物) raised USD 315 million in funding on April 20, with the financing round aimed at focusing on future mergers and acquisitions and product innovation, according to EqualOcean.

20 Chinese Companies to Watch in Q1 2023– Healthcare+

Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China’s healthcare space in Q1 2023. The following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, the activity level and the segments in which the startups operate.

Qiming-Backed Hochuen Medical Bags Over CNY 10 Mn in Series B Round

Microfluidics technology, at the core of point-of-care testing (POCT), has huge potential for growth.

Hemay Pharmaceutical Nets Nearly CNY 300 Mn in Series D

The innovative drug company aims to provide more effective, affordable, safer medicine for patients